GRACE Founder and President Dr. H. Jack West gives thanks to immunotherapies that offer new hope to his patients. November is Lung Cancer Awareness Month. What are you grateful for?

With the Thanksgiving holiday in November, the month has become synonymous with gratitude in the U.S. November is also Lung Cancer Awareness Month; an initiative started in 1995 to increase knowledge of the disease.

Even in the world of lung cancer, there are things to be grateful for. This November, join GRACE as we celebrate them with doctors, patients and caregivers.

The current standard of care for SCLC shows limited results with high toxicities. Drs. Soria, Gandhi, and West discuss new ASCO 2015 data that show promise for a subset of patients with PD-L1 expression on Keytruda (pembrolizumab) or Opdivo (nivolumab).

[powerpress]

As more immunotherapeutics become available to treat lung cancer, research must determine how to balance efficacy, toxicities, and cost. That means finding which patients who will benefit from which drugs while maintaining good quality of life.

[powerpress]

Novel immunotherapy agent atezolizumab (MPDL3280A) looks superior to Taxotere (docetaxel) in a study, specifically for patients with PD-L1. What are the implications of multiple agents with similar mechanisms of action in the same clinical settings?

[powerpress]

Immunotherapy Forum Video #26: Drs. Jared Weiss and Matthew Hellmann answer questions from the audience following their presentations on immunotherapy for lung cancer. Moderated by Dr. Jack West.

[powerpress]

Thoracic oncologist Dr. Ben Levy highlights what he believes was the biggest news for lung cancer patients in 2014 as well as his take on exciting clinical trials taking place in lung cancer in 2015.

Download a transcript of the video

[powerpress]

Immunotherapy Forum Video #25: In Part 2 of 2 videos, Dr.

Immunotherapy Forum Video #24: In Part 1 of 2 videos, Dr.